StudyFinder
A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Recruiting
We are running this research study to learn about Obeldesivir (ODV) for people with RSV infection who have not been hospitalized for treatment. People in the study will take ODV or placebo (an inactive substance) for up to 5 days.
Male or Female
18 years and over
Inclusion Criteria:
• at least 1 of the following risk factors for severe RSV disease: at least 60 years old, moderate or severe COPD, asthma with at least one exacerbation during the proceeding year, significant lung or heart disease
• positive test for RSV in the last 3 days
• if age is the only risk factor, must not have received the RSV vaccine
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
Exclusion Criteria:
• in the hospital, or expect to need hospitalization
• previous infection and/or hospitalization for RSV during the current respiratory virus season
• positive for influenza A or B virus, and/or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the past week
• history of cystic fibrosis
• require dialysis, known history of moderate or severe renal impairment
• women who are pregnant
Infectious Diseases
RSV infection
Natalie Eichten - eicht024@umn.edu
Jo-Anne Young, MD
PHASE2
STUDY00023194
See this study on ClinicalTrials.gov